| Literature DB >> 16107837 |
Jordan J Feld1, Jay H Hoofnagle.
Abstract
Since the identification of the hepatitis C virus, great strides have been made in the development of an antiviral therapy. As a crucial mediator of the innate antiviral immune response, interferon-alpha (IFN-alpha) was a natural choice for treatment. Whereas treatment with IFN-alpha alone achieved only modest success, the addition of the broad-spectrum antiviral agent ribavirin greatly improved responses. However, half of the infected individuals with chronic disease do not achieve sustained clearance of hepatitis C virus. To optimize current therapeutic strategies and to develop new therapies, a better understanding of the mechanism of action of IFN and ribavirin will be essential.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16107837 DOI: 10.1038/nature04082
Source DB: PubMed Journal: Nature ISSN: 0028-0836 Impact factor: 49.962